Development of pegylated liposomal vinorelbine formulation using "post-insertion" technology

International Journal of Pharmaceutics

Volumn 391, Issue 1-2, 2010, Pages 230-236

  Li, Chun Lei ^a,c   Cui, Jing Xia ^b   Wang, Cai Xia ^a,c   Zhang, Lan ^a,c   Li, Yan Hui ^a,c   Zhang, Li ^a,c   Xiu, Xian ^a,c   Li, Yong Feng ^a,c   Wei, Na ^a,c  

^a Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c Hebei Pharmaceutical Engineering and Technology Research Center   (China)

Author keywords

Active loading; DSPE PEG; Efficacy; Liposomes; Pharmacokinetics; Post insertion; Toxicity; Vinorelbine

Indexed keywords

LIPOSOME; MACROGOL; NAVELBINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INCUBATION TEMPERATURE; INCUBATION TIME; LEUKEMIA; MALE; MICELLE; MOUSE; NONHUMAN; POST INSERTION TECHNOLOGY; PRIORITY JOURNAL; PROSTATE TUMOR; SARCOMA; SINGLE DRUG DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; HUMANS; LIPOSOMES; MICE; MICE, INBRED STRAINS; POLYETHYLENE GLYCOLS; VINBLASTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77952951352     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.03.004     Document Type: Article

References (31)

1. Aapro M.S., Harper P., Johnson S.A., Vermorken J.B. Developments in cytotoxic chemotherapy: advances in treatment utilising vinorelbine. Crit. Rev. Oncol. Hematol. 2001, 40:251-263.
2. Allen T.M., Hansen C., Martin F., Redemann C., Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1991, 1066:29-36.
3. Cattel L., Ceruti M., Dosio F. From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Tumor 2003, 89:237-249.
4. Chow T.H., Lin Y.Y., Hwang J.J., Wang H.E., Tseng Y.L., Pang V.F., Liu R.S., Lin W.J., Yang C.S., Ting G. Therapeutic efficacy evaluation of 111In-labeled PEGylated liposomal vinorelbine in murine colon carcinoma with multimodalities of molecular imaging. J. Nucl. Med. 2009, 50:2073-2081.
5. Chow T.H., Lin Y.Y., Hwang J.J., Wang H.E., Tseng Y.L., Pang V.F., Wang S.J., Whang-Peng J., Ting G. Diagnostic and therapeutic evaluation of 111 In-vinorelbine-liposomes in a human colorectal carcinoma HT-29/luc-bearing animal model. Nucl. Med. Biol. 2008, 35:623-634.
6. Crawford J. Update: vinorelbine (navelbine) in non-small cell lung cancer. Semin. Oncol. 1996, 23:2-7.
7. Cui J., Li C., Guo W., Li Y., Wang C., Zhang L., Zhang L., Hao Y., Wang Y. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?. J. Control. Release 2007, 118:204-215.
8. Curran M.P., Plosker G.L. Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer. Drugs Aging 2002, 19:695-721.
9. Drummond D.C., Noble C.O., Guo Z., Hayes M.E., Park J.W., Ou C.J., Tseng Y.L., Hong K., Kirpotin D.B. Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine. J. Pharmacol. Exp. Ther. 2009, 328:321-330.
10. Gregory R.K., Smith I.E. Vinorelbine-a clinical review. Br. J. Cancer 2000, 82:1907-1913.
11. Haran G., Cohen R., Bar L.K., Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta 1993, 1151:201-215.
12. Iden D.L., Allen T.M. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim. Biophys. Acta 2001, 1513:207-216.
13. Johnson S.A. Vinorelbine: an update and review of activity. Clin. Oncol. (R. Coll. Radiol.) 1996, 8:353-357.
14. Johnson S.A., Harper P., Hortobagyi G.N., Pouillart P. Vinorelbine: an overview. Cancer Treat. Rev. 1996, 22:127-142.
15. Jones S.F., Burris H.A. Vinorelbine: a new antineoplastic drug for the treatment of non-small-cell lung cancer. Ann. Pharmacother. 1996, 30:501-506.
16. Karminsky N., Merimsky O., Kovner F., Inbar M. Vinorelbine-related acute cardiopulmonary toxicity. Cancer Chemother. Pharmacol. 1999, 43:180-182.
17. Kenworthy A.K., Hristova K., Needham D., McIntosh T.J. Range and magnitude of the steric pressure between bilayers containing phospholipids with covalently attached poly(ethylene glycol). Biophys. J. 1995, 68:1921-1936.
18. Krikorian A., Breillout F. Vinorelbine (Navelbine). A new semisynthetic vinca alkaloid. Onkologie 1991, 14:7-12.
19. Lasic D.D., Ceh B., Stuart M.C., Guo L., Frederik P.M., Barenholz Y. Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. Biochim. Biophys. Acta 1995, 1239:145-156.
20. Moreira J.N., Ishida T., Gaspar R., Allen T.M. Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity. Pharm. Res. 2002, 19:265-269.
21. Nabiev I., Fleury F., Kudelina I., Pommier Y., Charton F., Riou J.F., Alix A.J., Manfait M. Spectroscopic and biochemical characterisation of self-aggregates formed by antitumor drugs of the camptothecin family: their possible role in the unique mode of drug action. Biochem. Pharmacol. 1998, 55:1163-1174.
22. Needham D., Stoicheva N., Zhelev D.V. Exchange of monooleoylphosphatidylcholine as monomer and micelle with membranes containing poly(ethylene glycol)-lipid. Biophys. J. 1997, 73:2615-2629.
23. Semple S.C., Leone R., Wang J., Leng E.C., Klimuk S.K., Eisenhardt M.L., Yuan Z.N., Edwards K., Maurer N., Hope M.J., Cullis P.R., Ahkong Q.F. Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. J. Pharm. Sci. 2005, 94:1024-1038.
24. Siegal T., Horowitz A., Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J. Neurosurg. 1995, 83:1029-1037.
25. Sorensen J.B. Vinorelbine. A review of its antitumour activity in lung cancer. Drugs 1992, 44(Suppl 4):60-65. discussion 66-69.
26. Takeuchi H., Kojima H., Yamamoto H., Kawashima Y. Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats. J. Control. Release 2001, 75:83-91.
27. Vail D.M., Kurzman I.D., Glawe P.C., O'Brien M.G., Chun R., Garrett L.D., Obradovich J.E., Fred R.M., Khanna C., Colbern G.T., Working P.K. STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial. Cancer Chemother. Pharmacol. 2002, 50:131-136.
28. Webb M.S., Johnstone S., Morris T.J., Kennedy A., Gallagher R., Harasym N., Harasym T., Shew C.R., Tardi P., Dragowska W.H., Mayer L.D., Bally M.B. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. Eur. J. Pharm. Biopharm. 2007, 65:289-299.
29. Webb M.S., Saxon D., Wong F.M., Lim H.J., Wang Z., Bally M.B., Choi L.S., Cullis P.R., Mayer L.D. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim. Biophys. Acta 1998, 1372:272-282.
30. Zhigaltsev I.V., Maurer N., Akhong Q.F., Leone R., Leng E., Wang J., Semple S.C., Cullis P.R. Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. J. Control. Release 2005, 104:103-111.
31. Zhigaltsev I.V., Maurer N., Edwards K., Karlsson G., Cullis P.R. Formation of drug-arylsulfonate complexes inside liposomes: a novel approach to improve drug retention. J. Control. Release 2006, 110:378-386.